Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5558864A · kind A · utility
310Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 6, 1992 |
| Grant date | Sep 24, 1996 |
| Priority date | — |
| Expiry date | Nov 6, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Humanized and chimeric anti-epidermal growth factor receptor (anti-EGF-R) monoclonal antibodies are disclosed, comprising an artificial modified consensus sequence for the heavy chain of the framework region of the variable region of a human immunoglobulin. Corresponding humanized and chimeric monoclonal antibodies which bind to epitopes of the epidermal growth factor receptor (EGF-R) having specific amino acid sequences in the hypervariable regions responsible for EGF-R binding are also disclosed. These antibodies are therapeutically and diagnostically useful.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.